Low-grade Lymphoproliferative Disorders (CLL, HCL, T-PLL) – Adult[1]

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

Note: Consider Clinical Trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.



CLL = chronic lymphocytic leukemia
HCL = hairy cell leukemia
T-PLL = t-cell prolymphocytic leukemia
IGVH = immunoglobulin heavy-chain variable-region

[1] Greater than or equal to 18 years old
[2] See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice
[3] Leukemia Newsletter: http://www.mdanderson.org/leukemia

Department of Clinical Effectiveness V6
Approved by The Executive Committee of the Medical Staff 02/26/2019

SUGGESTED READINGS

Burger, J., Tedeschi, A., Barr, P., Robak, T., Owen, C., Ghia, P., … Kipps, T. (2015). Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. *The New England Journal of Medicine*, *373*(25), 2425–2437. https://doi.org/10.1056/NEJMoa1509388

Byrd, J., Brown, J., O'Brien, S., Barrientos, J., Kay, N., Reddy, N., … Hillmen, P. (2014). Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. *The New England Journal of Medicine*, *371*(3), 213–223. https://doi.org/10.1056/NEJMoa1400376

Byrd, J., Furman, R., Coutre, S., Burger, J., Blum, K., Coleman, M., … O'Brien, S. (2015). Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*, *125*(16), 2497–2506. https://doi.org/10.1182/blood-2014-10-606038

Byrd, J., Furman, R., Coutre, S., Flinn, I., Burger, J., Blum, K., … O'Brien, S. (2013). Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. *The New England Journal of Medicine*, *369*(1), 32–42. https://doi.org/10.1056/NEJMoa1215637

Furman, R., Sharman, J., Coutre, S., Cheson, B., Pagel, J., Hillmen, P., … O'Brien, S. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. *The New England Journal of Medicine*, *370*(11), 997–1007. https://doi.org/10.1056/NEJMoa1315226

Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C., … Hallek, M. (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. *The New England Journal of Medicine*, *370*(12), 1101–1110. https://doi.org/10.1056/NEJMoa1313984

Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L., … Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study.(Letters to the Editors)(Letter to the editor). *Leukemia*, *29*(7), 1602–1604. https://doi.org/10.1038/leu.2015.14

Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., … Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. *The Lancet*, *376*(9747), 1164–1174. https://doi.org/10.1016/S0140-6736(10)61381-5

National Comprehensive Cancer Network. (2018). *Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma* (NCCN Guideline Version 5.2018). https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf.

Seymour, J., Kipps, T., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., … Kater, A. (2018). Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. *The New England Journal of Medicine*, *378*(12), 1107–1120. https://doi.org/10.1056/NEJMoa1713976

Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J., Munir, T., … Wierda, W. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study. *The Lancet Oncology*, *17*(6), 768–778. https://doi.org/10.1016/S1470-2045(16)30019-5

Low-grade Lymphoproliferative Disorders (CLL, HCL, T-PLL) – Adult

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Yesid Alvarado, MD (Leukemia)
Michael Andreeff, PhD, MD (Leukemia)
Christopher Benton, MD (Leukemia)
Kapil Bhalla, MD (Leukemia)
Gautam Borthakur, MBBS (Leukemia)
Prithviraj Bose, MD (Leukemia)
Jan Burger, MD (Leukemia)
Jorge Cortes, MD (Leukemia)
Naval Daver, MD (Leukemia)
Courtney DiNardo, MD (Leukemia)
Zeev Estrov, MD (Leukemia)
Alessandra Ferrajoli, MD (Leukemia)[Ŧ]
Emil Freireich, MD (Leukemia)
Wendy Garcia, BS[♦]
Guillermo Garcia-Manero, MD (Leukemia)
Ghayas Issa, MD (Leukemia)
Elias Jabbour, MD (Leukemia)
Nitin Jain, MBBS (Leukemia)
Tapan Kadia, MD (Leukemia)
Hagop M. Kantarjian, MD (Leukemia)[Ŧ]
Michael Keating, MD (Leukemia)
Marina Konopleva, MD (Leukemia)
Steven Kornblau, MD (Leukemia)
Lucia Masarova, MD (Leukemia)
Guillermo Montalban-Bravo, MD (Leukemia)
Kiran Naqvi, MD (Leukemia)
Maro Ohanian, DO (Leukemia)
Naveen Pemmaraju, MD (Leukemia)
Farhad Ravandi-Kashani, MD (Leukemia)
Michael Rytting, MD (Pediatrics)
Koji Sasaki, MD (Leukemia)
Nicholas Short, MD (Leukemia)
Koichi Takahashi, MD (Leukemia)
Philip Thompson, MBBS (Leukemia)
Srdan Verstovsek,MD (Leukemia)
William Wierda, MD (Leukemia)[Ŧ]
Sonal Yang, PharmD[♦]
Musa Yilmaz, MD (Leukemia)

[Ŧ] Core Development Leads
[♦] Clinical Effectiveness Development Team